Acasă › Leucemie mieloasă acută › Minnesota › Minneapolis
Studii clinice pentru Leucemie mieloasă acută în Minneapolis, MN
20 studii pentru Leucemie mieloasă acută caută participanți în și în jurul orașului Minneapolis (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
În curs de recrutareFaza 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · La 5 mi distanță
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
În curs de recrutareFaza 1
- University of Minnesota/Masonic Cancer Center, Minneapolis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · La 5 mi distanță
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
În curs de recrutareFaza 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · La 5 mi distanță
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
În curs de recrutareFaza 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · La 5 mi distanță
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
În curs de recrutareFaza 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · La 5 mi distanță
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
În curs de recrutareFaza 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · La 5 mi distanță
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
În curs de recrutareFaza 3
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
În curs de recrutareFaza 1/2
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
În curs de recrutareFaza 3
- Masonic Cancer Center, Minneapolis
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
În curs de recrutareFaza 3
- University of Minnesota, Minneapolis
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
În curs de recrutareFaza 1/2
- Masonic Cancer Center, Minneapolis
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
În curs de recrutareFaza 1
- Masonic Cancer Center, Minneapolis
Allo HSCT Using RIC and PTCy for Hematological Diseases
În curs de recrutareFaza 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
În curs de recrutareFaza 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
În curs de recrutareFaza 1/2
- Mark Juckett, MD, Minneapolis
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
În curs de recrutareFaza 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
În curs de recrutareStudiu observațional
- University of Minnesota/Masonic Cancer Center, Minneapolis
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
În curs de recrutareFaza 2
- University of Minnesota Masonic Cancer Center, Minneapolis
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
În curs de recrutareFaza 1
- University of Minnesota, Minneapolis
Studii pentru Leucemie mieloasă acută în alte orașe
- Houston, TX85 studii
- New York City, NY51 studii
- Boston, MA44 studii
- Seattle, WA41 studii
- Baldwin Park, CA40 studii
- Columbus, OH35 studii
- Philadelphia, PA34 studii
- Durham, NC33 studii
- Atlanta, GA31 studii
- Tampa, FL29 studii
- Chicago, IL26 studii
- Portland, OR25 studii
Alte studii în Minneapolis
- Cancer pulmonar cu celule non-pătrate27 studii
- Cancer de sân27 studii
- Cancer ovarian24 studii
- Cancer de prostată23 studii
- Cancer (toate tipurile)22 studii
- Insuficiență cardiacă21 studii
- Cancer pulmonar20 studii
- Cancer colorectal19 studii
- Cancer endometrial18 studii
- Boala Parkinson17 studii
- Boli cardiovasculare15 studii
- Boală coronariană13 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.